Baxter (BAX) has appointed Heather Knight to the role of executive vice president and COO, effective immediately. As COO, Knight will have responsibility for the company’s day-to-day business operations, including global sales, marketing, R&D, supply chain and medical and regulatory affairs. She will report directly to the interim CEO and will also serve as interim group president, Medical Products & Therapies.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Baxter Kidney Care becomes Vantive following acquisition by Carlyle funds
- Baxter International Announces New Chief Accounting Officer
- Baxter price target lowered to $42 from $45 at Evercore ISI
- Early notable gainers among liquid option names on December 20th
- Baxter price target lowered to $35 from $37 at Citi